Analysts cut target prices on HOLX stock
Hologic (HOLX) is a medical technology company focused on women’s health with headquarters in Marlborough, Massachusetts. The company offers solutions across four segments including diagnostics, breast and skeletal health, gynecological surgery, and medical aesthetics. The company recently provided an update on the financial impact of its recently announced marketing and distribution suspension of its TempSure Vitalia handpiece and probes. We discussed the details in the previous article of this series. A number of analysts made a downward revision to their recommendations and target prices on HOLX stock following the update.
Recent ratings and target price updates
On September 13, Canaccord Genuity cut its target price on Hologic from $41 to $40. The firm has a “hold” recommendation on HOLX stock. On the same day, Bank of America Merrill Lynch downgraded HOLX stock from “buy” to “neutral.” The firm decreased the price target from $47 to $42.
Consensus target price and analysts’ recommendations
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation. The remaining nine analysts have a “hold” rating on the stock. None of the analysts provided a “sell” rating on Hologic.
As of September 18, the consensus analyst target price for HOLX stock for the next 12 months is $44.73. This target price represents a 12-month investment return of ~13.2%. This return is based on Hologic’s closing price of $39.53 on September 17.
Analysts’ average target prices for HOLX peers Illumina (ILMN), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO) are $343.07, $39.32, and $252.86, respectively, implying -1.2%, 5.5%, and 6% returns over the next 12 months.